Issue 120

cost-benefit of MDMA-assisted therapy

The cost-benefit of MDMA-assisted therapy for PTSD

MAPS recently announced positive results from its second Phase III trial with MDMA-assisted therapy in the treatment of PTSD, with top-line data expected to be published in a peer-reviewed journal in the coming weeks.

In the US, 900,000 veterans with PTSD receive disability payments from the Department of Veterans Affairs – totalling US$17 billion annually.

Mitigating this economic burden is a key driver behind the urgency to find an effective treatment for the disorder, with the treatment’s cost-effectiveness of paramount importance not only to government payers, such as the Veterans Administration, but also to private insurers.

READ MORE

OBTAINING QUANTITATIVE DATA IN PSYCHEDELIC-ASSISTED THERAPY

Cybin’s CEO, Doug Drysdale, spoke with Psychedelic Health about the use of Kernel’s wearable technology.

Read More

EUROPEAN REGULATORS URGED TO RESCHEDULE PSYCHEDELICS

MEPs have expressed concern over the lack of progress within the EU on the clinical use of psychedelic medicine.

Read More

BUSINESS AND INVESTMENT

Awakn opens second clinic in Norway and signs licensing agreement in Portugal.

LongeVC invests in psychedelic healthcare.

The combination of VR and psychedelic-assisted therapy.

FDA approves Beckley Psytech’s 5-MeO-DMT study.

Small Pharma doses first patient in DMT study.

Algernon launches programme to treat traumatic brain injury.

SCIENCE AND RESEARCH

Why Europe needs to catch up with psychedelic research.

How psychedelic medicines instigate neuroplasticity.

Unblinded clinical trials in psychedelic research.

Cardiovascular effects of bufotenin on serotonin receptors.

The market for MDMA-assisted therapy could be worth over US$1 billion by 2026.

The Psychedelics as Medicine Report: Fourth Edition provides industry intelligence, empowering investors to make informed decisions.

COMPLIMENTARY DOWNLOAD

REGULATION AND LEGISLATION

Washington senators strip bill to legalise psilocybin.

Lawmakers in Virginia vote against rescheduling psilocybin.

Regulatory reform regarding psychedelic medicine in 2022.

Oklahoma house committee approves bill to research psilocybin-assisted therapy.

Scientists argue rescheduling in Australia may be premature.

Would your organisation benefit from engaging with Europe’s psychedelic medicine community?

Event partnership provides the opportunity to engage with an audience ready to support the development of psychedelic healthcare.

Previous partners include COMPASS Pathways, Beckley Psytech and Awakn Life Sciences.

PARTNERSHIP OPPORTUNITIES

ARTICLES OF INTEREST

Local authorities in England to receive £421m to treat drug addiction.

The association of severe COVID anxiety with poor social functioning.

UK police dealing with more people experiencing mental health crises.

Thinking beyond the 12-step addiction recovery programmes.

Do you know a spokesperson who could provide insights on the future of psychedelic healthcare?

Previous symposium speakers include:

  • Rick Doblin – Founder, MAPS
  • Cosmo Feilding Mellen – CEO, Beckley Psytech
  • Carol Routledge – Chief Medical and Scientific Officer, Small Pharma
  • MP Crispin Blunt – Chair, The Conservative Drug Policy Reform Group
SPEAKING OPPORTUNITIES
Partner with us